Last reviewed · How we verify
KPCXM18
At a glance
| Generic name | KPCXM18 |
|---|---|
| Sponsor | Kunming Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke (PHASE2)
- Study of the KPCXM18 Injection for Treatment of Acute Ischemic Stroke (PHASE2)
- Safety,Tolerability, and Pharmacokinetic of KPCXM18 for Injection (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KPCXM18 CI brief — competitive landscape report
- KPCXM18 updates RSS · CI watch RSS
- Kunming Pharmaceuticals, Inc. portfolio CI